Min Huang

Publication Activity (10 Years)

Years Active: 2018-2023
Publications (10 Years): 5

Top Topics

Epidermal Growth Factor Receptor

Systematic Review

Small Cell Lung Cancer

Affordable Care Act

Top Venues

PharmacoEconomics

PharmacoEconomics - open

This page only lists publications with an associated author ORCID identifier.

Publications

Andrea Favre-Bulle, Min Huang, Amin Haiderali, Arjun Bhadhuri
Cost-Effectiveness of Neoadjuvant Pembrolizumab plus Chemotherapy Followed by Adjuvant Pembrolizumab in Patients with High-Risk, Early-Stage, Triple-Negative Breast Cancer in Switzerland. PharmacoEconomics - open (2023)
Min Huang, Amin Haiderali, Grace E Fox, Andrew Frederickson, Javier Cortes, Peter A Fasching, Joyce O'Shaughnessy
Economic and Humanistic Burden of Triple-Negative Breast Cancer: A Systematic Literature Review. PharmacoEconomics 40 (5) (2022)
Min Huang, Scott Ramsey, Weiguang Xue, Jipan Xie, James Pellissier, Andrew Briggs
Conceptual Framework and Methodological Challenges for Modeling Effectiveness in Oncology Treatment Sequence Models. PharmacoEconomics (2021)
Min Huang, M Catherine Pietanza, Ayman Samkari, James Pellissier, Thomas Burke, Sheenu Chandwani, Fansen Kong, A Simon Pickard
Q-TWiST Analysis to Assess Benefit-Risk of Pembrolizumab in Patients with PD-L1-Positive Advanced or Metastatic Non-small Cell Lung Cancer. PharmacoEconomics 37 (1) (2020)
Min Huang, Yanyan Lou, James Pellissier, Thomas Burke, Frank Xiaoqing Liu, Ruifeng Xu, Vamsidhar Velcheti
Cost Effectiveness of Pembrolizumab vs. Standard-of-Care Chemotherapy as First-Line Treatment for Metastatic NSCLC that Expresses High Levels of PD-L1 in the United States. PharmacoEconomics 35 (8) (2018)